HC Wainwright Reaffirms “Buy” Rating for CG Oncology (NASDAQ:CGON)

HC Wainwright reiterated their buy rating on shares of CG Oncology (NASDAQ:CGON – Free Report) in a research note released on Tuesday morning, Benzinga reports. The brokerage currently has a $75.00 target price on the stock. Several other research firms also recently commented on CGON. Bank of America assumed coverage on CG Oncology in a […]

Leave a Reply

Your email address will not be published.

Previous post DMC Global (NASDAQ:BOOM) PT Lowered to $17.00 at Stifel Nicolaus
Next post EnLink Midstream (NYSE:ENLC) Lowered to “Equal Weight” at Morgan Stanley